ALTSTATION.IO

Edwards Lifesciences Corporation (EW) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$78.09

Change

-0.01%

Market Cap

$45.85B

Avg Volume

3.5M

Company Overview

Edwards Lifesciences Corporation, based in Irvine, California, specializes in medical devices that treat advanced cardiovascular diseases. Their primary offerings include transcatheter heart valve replacement products like the Edwards SAPIEN valves, designed for minimally invasive aortic heart valve replacements. They also produce devices for repairing mitral and tricuspid valves, known under the PASCAL PRECISION and Cardioband brands. Their surgical structural heart solutions include various aortic valves branded as INSPIRIS. Edwards Lifesciences serves hospitals and healthcare providers globally, operating mainly in the United States, Europe, and Japan.

Edwards is a market leader in the transcatheter heart valve sector, boasting a significant share of the growing market for minimally invasive heart procedures. Their edge comes from innovation, a strong product pipeline, and a robust distribution network through direct sales and independent distributors. However, competition is fierce, especially from companies like Medtronic and Boston Scientific, which also target cardiovascular technology. As the healthcare industry shifts toward more minimally invasive treatments, Edwards must continuously innovate to fend off growing rivals and maintain its lead.

Currently, Edwards is experiencing growth, driven by rising demand for transcatheter heart valve procedures. Recent milestones include the successful launch of next-generation products that enhance procedural outcomes. The company’s strategic focus is on expanding its reach in international markets and investing heavily in research and development. This commitment positions them well to capture future market share as cardiovascular disease treatment trends evolve.

Key Financials

Market Cap

$45.85B

Revenue

$5.88B

EBITDA

$1.79B

Gross Margin

78.2%

Profit Margin

23.2%

Revenue Growth

14.7%

Total Cash

$3.84B

Total Debt

$700.30M

Free Cash Flow

$524.50M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

34.25

Forward P/E

26.81

Beta

0.94

52-Week High

$87.89

52-Week Low

$65.94

EPS

$2.28

50-Day Avg

$84.37

200-Day Avg

$79.47

Price/Book

4.44

Technical Analysis

Over the past 52 weeks, Edwards Lifesciences Corporation (EW) has demonstrated a generally upward trend, with a notable price increase of 10.7%, although it has faced some recent volatility. Key support is observed around the $70 level, which has held firm multiple times during pullbacks, while resistance appears near $85, where the price has struggled to maintain momentum. A prominent price pattern is the ascending triangle formation leading into the recent highs, suggesting a bullish sentiment until the past few weeks where it has pulled back. Recent momentum has shifted, as indicated by the drop below the established uptrend line; this suggests weakening bullish sentiment. Currently priced at $78.09, Edwards is situated approximately 7% above the support level, indicating a relatively stable position, but below the yearly high, which could imply potential resistance ahead.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Edwards Lifesciences Corporation (EW) stock in the past week:

Market Update

### Edwards Lifesciences Awaits Key FDA Decision on SAPIEN M3 Mitral Valve System

Market Update

Edwards Lifesciences (NYSE: EW) is nearing a significant regulatory milestone with an upcoming FDA decision on its SAPIEN M3 Transcatheter Mitral Valve Replacement system. This potential approval is viewed as a crucial development for the company’s structural heart portfolio, especially as the SAPIEN M3 system recently achieved its primary endpoint in the ENCIRCLE trial for mitral replacement. Ins

Market Sentiment and Analyst Recommendations

Bull Case

Edwards is firing on multiple cylinders right now. Revenue growth at 14.7% is solid for a $5.88B company, and the SAPIEN M3 FDA decision is a genuine catalyst that could unlock meaningful upside in mitral valve replacement — a massive addressable market. The balance sheet is fortress-like: $3.84B cash against only $700M debt gives them firepower for R&D and M&A (though the JenaValve block stings). Analyst consensus is overwhelmingly bullish with 28 buy ratings and a $96.98 median target, implying 24% upside from current levels. The stock is up 10.7% over 52 weeks despite recent weakness, and at $78.09 it’s only 7% above the $70 support level, offering a reasonable risk-reward for structural heart investors betting on continued TAVR adoption and aging demographics.

Bear Case

The valuation is stretched at 34.25x P/E, which leaves zero room for disappointment. The JenaValve acquisition block is a real problem — it signals the FTC is hostile to Edwards’ consolidation strategy in TAVR, limiting future growth options and forcing the company to innovate internally. Recent price action is troubling: down 2.7% over the past week, broke below the uptrend line, and momentum has shifted negative despite positive fundamentals. The stock is trading near resistance at $85 and vulnerable if the SAPIEN M3 FDA decision disappoints or gets delayed. Structural heart is increasingly competitive, and Edwards faces pressure from Boston Scientific, Abbott, and others. At these valuations, execution has to be flawless, and the FTC loss suggests regulatory risk is real.

What to Watch

The SAPIEN M3 FDA decision is the immediate catalyst — approval would likely drive a 5-8% pop, while rejection or delay could trigger a 10%+ selloff given how much is priced in. Q4 2025 earnings on February 10th matter because the company beat badly in Q3 with $0.90 EPS; any guidance cut or slowdown in structural heart growth would be damaging at current multiples. Monitor the $85 resistance level closely — if the stock breaks above it on volume, the uptrend resumes and $96.98 becomes realistic. Conversely, if it fails to hold $70 support, the bull thesis breaks. Watch for any commentary on pipeline innovation post-JenaValve block — does management articulate a credible path to replace that mitral valve upside internally? Finally, track competitive wins and market share in TAVR; if Edwards starts losing share to Abbott or Boston Scientific, the 14.7% revenue growth story stalls fast.

Analyst Consensus

BUY

Based on 28 analyst opinions

Low Target

$84.00

Mean Target

$96.98

High Target

$110.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

15,800

Earnings & Dividends

Next Earnings

Feb 10, 2026

EPS (Trailing)

$2.28

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is EW a good stock to buy?

Analysts currently recommend a BUY for Edwards Lifesciences, with a target price of $96.98. Given its strong position in the medical devices sector and growth potential, it’s a solid investment option.

What is EW’s price target?

The consensus price target for Edwards Lifesciences is $96.98. This suggests a potential upside of about 24% from the current price of $78.09.

Does EW pay a dividend?

Edwards Lifesciences does not pay a dividend. While this may deter income-focused investors, the stock’s growth potential could be more attractive for those looking for capital appreciation.

What is EW’s P/E ratio?

Edwards Lifesciences has a P/E ratio of 34.25 and a forward P/E of 26.81. This indicates the stock is priced for growth, reflecting investor expectations for future earnings increases.

How has EW performed over the past year?

The stock has traded within a 52-week range of $65.94 to $87.89. Currently priced at $78.09, it sits in the middle of its range, suggesting that it could either be undervalued or facing resistance near its highs.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.